Pipeline
Solid Tumor Program
TScan is developing multiplex TCR-T therapy to treat solid tumors. Our vision is to expand the ImmunoBank, a repository of TCRs across multiple targets and HLA types, to provide tailored therapies for patients with various types of solid tumors.
- Our TCR-T therapies are designed to be administered as both a single product or in combination with each other as a multiplexed treatment to help reduce the risk of resistance driven by target loss or HLA loss. We are currently engaged in preclinical development of in vivo-engineered T cells using the TCRs in our ImmunoBank, with the goal of delivering an off-the-shelf T-cell product to patients.
- Targets are shared among patients with the same cancer type, and are also expressed across different solid tumor types, enabling clinical development in multiple indications.
- Targets are frequently expressed in high-incidence solid tumors that are heterogenous by nature, including NSCLC, sarcoma, head & neck, cervical, anal, and genital cancer.
- We believe that by targeting more than one antigen expressed in a tumor, we are positioned to improve response rates as well as duration of response in these difficult-to-treat solid tumor indications.
